About Avanti NanoSciences  

Avanti NanoSciences is focused on the Life Science market segments that consistently demand new and innovative technologies to further research, development and clinical capabilities. These markets already represent a $32 billion opportunity that is rapidly growing based on the availability of new and innovative enabling technologies. Capturing market share with attractive and sustainable returns on investment is definitely achievable.

Despite their value, current technologies have significant limitations preventing their utility in broader research and diagnostic applications where rapid, accurate and cost-effective analysis of multi parameter testing is critical. Current immunological or PCR based methods do not provide a high level of sensitivity or reproducibility and are expensive and time-consuming. Various template amplification technologies provide sensitive and reproducible analysis but are limited to analyzing up to 4 to 5 genes at a time and thereby become prohibitively expensive for monitoring larger sets of expressed biomarkers.

Avanti NanoSciences is developing a innovative detection and monitoring process referred to as Life Sciences at Speed of Light (LSSL). LSSL integrates a number of well-defined procedures in a proprietary and innovative manner that allows for significant technical advantages over existing biomarker detection and monitoring techniques as well as dramatic cost-savings on a per biomarker basis. Avanti’s proprietary NanoBindi/GateKeeper ID technology platform can rapidly identify and monitor multiple targets simultaneously from a single sample with levels of sensitivity, reproducibility, and accuracy equal to or better than today's standards for single target detection, thus far surpassing the performance of current multi-target detection diagnostic platforms.

Importantly, no other solution addresses the needs of life science applications requiring both a high density and high throughput at the same time. Traditional ELISA, real-time PCR and other technologies that excel at high-throughput applications (greater than 1000 samples per day) lack the ability to multiplex more than 5 tests at a time. On the other hand, microarray technology excels in high-density screening (greater than 250-plex tests) — but lacks the reproducibility needed for high-throughput applications.  The requirement of robotic sample dispensing and labile reagents is another limitation of these technologies and introduces variability in the assay system. The reagent-free methodology being developed by Avanti NanoSciences with multi-parameter testing of target molecules with parallel processing offers unique market advantages in this competitive market place. 

The current biomarker detection, identification and monitoring systems rely on complex technology that is laboratory based and tend to be time-consuming, expensive, and requires relatively large samples and process methodology steps that increase the risk of process and human error. Even though there are number of companies developing different nanoparticles, there are very few companies that develop life science applications using nanoparticles. Most companies use either cytotoxic heavy metal cages (Quantum dots) or expensive gold or silver nanoparticles. Avanti Nanosciences’ uses their proprietary NanoBindis-commonly used fluorescent dye core with inexpensive silica shells. Our strategy to develop domain specific bionanotechnology applications and IP Estate, will establish and help us maintain a leadership position in this fast growing market segment. 

Investors

Founded as a spin-off of AT-GC in late 2006, Avanti NanoSciences is a privately held firm based in Baltimore, Maryland that is backed by AT-GC and founding members.

More»